Empowered Funds’s Roivant Sciences ROIV Stock Holding History

Empowered Funds’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.49M	Sell	268,158 -17,757	-6%	-$525K	0.05%	434
2026 Q1	$7.92M	Buy	285,915 +267,686	+1,468%	+$6.88M	0.05%	469
2025 Q4	$396K	Buy	+18,229	New	+$360K	0.01%	798
2023 Q4	–	Sell	-264,661	Closed	-$3.09M	–	1307
2023 Q3	$3.09M	Buy	+264,661	New	+$2.99M	0.09%	302

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Empowered Funds's ROIV Position: Q2 2026 in Review

Empowered Funds reduced its Roivant Sciences (ROIV) stake by 6.2% in Q2 2026, selling an estimated $525K and leaving 268,158 shares worth $9.49M. The position accounts for 0.05% of the portfolio, ranked #434.

Empowered Funds first reported a position in ROIV in Q3 2023 and has held it in 4 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Empowered Funds held 268,158 shares of Roivant Sciences worth $9.49M as of Q2 2026.
Empowered Funds sold 17,757 Roivant Sciences shares in Q2 2026, an estimated $525K.
Roivant Sciences made up 0.05% of Empowered Funds's portfolio in Q2 2026, its #434 holding.
Empowered Funds first reported a position in Roivant Sciences in Q3 2023 and has held it in 4 quarters since.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.